These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4405 related articles for article (PubMed ID: 21633166)

  • 1. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
    Lehmann BD; Bauer JA; Chen X; Sanders ME; Chakravarthy AB; Shyr Y; Pietenpol JA
    J Clin Invest; 2011 Jul; 121(7):2750-67. PubMed ID: 21633166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
    Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
    BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles.
    Akhouayri L; Ostano P; Mello-Grand M; Gregnanin I; Crivelli F; Laurora S; Liscia D; Leone F; Santoro A; Mulè A; Guarino D; Maggiore C; Carlino A; Magno S; Scatolini M; Di Leone A; Masetti R; Chiorino G
    Hum Genomics; 2022 Dec; 16(1):70. PubMed ID: 36536459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
    Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
    Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
    Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
    Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
    Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular stratification within triple-negative breast cancer subtypes.
    Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
    Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
    Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
    Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers.
    Limsakul P; Choochuen P; Charupanit G; Charupanit K
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
    Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
    J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
    Basho RK; Zhao L; White JB; Huo L; Bassett RL; Mittendorf EA; Thompson A; Litton JK; Ueno N; Arun B; Lim B; Valero V; Tripathy D; Zhang J; Adrada BE; Santiago L; Ravenberg E; Seth S; Yam C; Moulder SL; Damodaran S
    JCO Precis Oncol; 2024 Mar; 8():e2300124. PubMed ID: 38484209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes
    Olsson M; Larsson P; Johansson J; Sah VR; Parris TZ
    Front Cell Dev Biol; 2023; 11():1237673. PubMed ID: 37771376
    [No Abstract]   [Full Text] [Related]  

  • 15. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
    Yoo TK; Kang J; Lee A; Chae BJ
    Breast Cancer Res Treat; 2022 Feb; 191(3):599-610. PubMed ID: 35018542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.
    Harano K; Wang Y; Lim B; Seitz RS; Morris SW; Bailey DB; Hout DR; Skelton RL; Ring BZ; Masuda H; Rao AUK; Laere SV; Bertucci F; Woodward WA; Reuben JM; Krishnamurthy S; Ueno NT
    PLoS One; 2018; 13(10):e0204513. PubMed ID: 30312311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines.
    Kumar S; Bhattacharyya S; Das A; Singh G; Bal A
    Breast Dis; 2022; 41(1):241-247. PubMed ID: 35431224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting triple-negative breast cancer: A clinical perspective.
    Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
    Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
    Robles AJ; Cai S; Cichewicz RH; Mooberry SL
    Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 221.